Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Ongoing, recruiting
Participants planned
117
Countries
5
Sites
20
Non-Hodgkin lymphoma and chronic lymphocytic leukemia
Key facts
- Sponsor
- Janssen Cilag International
- Participant type
- Patients
- Age range
- 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Neoplasms [C04]
- Trial duration
- 30 Dec 2024 → ongoing
- Decision date (initial)
- 2024-12-18
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Non-Hodgkin lymphoma and chronic lymphocytic leukemia
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 23.1 | LLT | 10084346 | B-cell non-Hodgkin´s lymphoma | 100000004848 |
| 21.0 | LLT | 10008976 | Chronic lymphocytic leukemia | 10029104 |
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Janssen Cilag International
- Sponsor organisation
- Janssen Cilag International
- Address
- Turnhoutseweg 30
- City
- Beerse
- Postcode
- 2340
- Country
- Belgium
Scientific contact point
- Organisation
- Janssen Cilag International
- Contact name
- CTIS Point of Contact
Public contact point
- Organisation
- Janssen Cilag International
- Contact name
- CTIS Point of Contact
Locations
5 EU/EEA countries · 20 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Belgium | Ongoing, recruiting | 1 | 1 |
| France | Ongoing, recruiting | 5 | 6 |
| Greece | Ongoing, recruiting | 1 | 1 |
| Poland | Ongoing, recruiting | 30 | 4 |
| Spain | Ongoing, recruiting | 15 | 8 |
| Rest of world
Australia, Georgia, Israel, United States, Japan, Moldova, Republic of, Korea, Republic of, Taiwan, Ukraine, United Kingdom
|
— | 65 | — |
Investigational sites
Centre Hospitalier Universitaire De Lille
Hopital Claude Huriez - Service des Maladies du sang, Rue Michel Polonowski, 59000, Lille
Institut Paoli Calmettes
Hematology Department, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille
Centre Hospitalier Universitaire De Nantes
Clinical Hematology, 1 Place Alexis Ricordeau, 44000, Nantes
Institut Gustave Roussy
Département d’Innovations Thérapeutiques et d’essais Précoces (DITEP), 114 Rue Edouard Vaillant, 94800, Villejuif
Institut Curie
Unité d’Investigation Clinique Adulte, 26 Rue D Ulm, 75005, Paris
Oncopole Claudius Regaud
Institut Universitaire du Cancer I.U.C.Toulouse – Oncopôle Département Hématologie, 1 Avenue Irene Joliot Curie, 31100, Toulouse
General Hospital Of Athens Alexandra
Department of Clinical Therapeutics, Vassilissis Sofias Avenue 80, 115 28, Athens
Pratia S.A.
Pratia MCM, Ul. Pana Tadeusza 2, 30-727, Cracow
Pratia Hematologia Sp. z o.o.
Pratia Onkologia Katowice, Ul. Tadeusza Kosciuszki 92, 40-519, Katowice
Uniwersyteckie Centrum Kliniczne
Osrodek Badan Klinicznych Wczesnych Faz, Ul. Mariana Smoluchowskiego 17, 80-214, Gdansk
Aidport Sp. z o.o.
Aidport Sp z o o, Ul Ksiedza Stanisława Kozierowskiego 24, 60-185, Skorzewo
Clinica Universidad De Navarra
Hematology Department, Pio XII Etorbidea 36, 31008, Pamplona
Clinica Universidad De Navarra
Hematology Department, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Clinic De Barcelona
Hematology Department, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario 12 De Octubre
Hematology Department, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitario De Salamanca
Hematology Department, Paseo De San Vicente 58-182, 37007, Salamanca
Hospital Universitari Vall D Hebron
Oncology department, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Oncology department, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitari Vall D Hebron
Hematology Department, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Belgium | 2025-01-13 | 2025-01-13 | |||
| France | 2025-02-06 | 2025-02-06 | |||
| Greece | 2025-02-27 | 2025-02-27 | |||
| Poland | 2024-12-30 | 2024-12-30 | |||
| Spain | 2025-08-25 | 2025-08-25 |
Application history
8 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-08-27 | France | Acceptable 2024-12-16
|
2024-12-16 |
| 2 | SUBSTANTIAL MODIFICATION | SM-1 | 2025-01-24 | France | Acceptable 2025-04-04
|
2025-04-07 |
| 3 | SUBSEQUENT ADDITION OF MSC | APP-3 | 2025-04-30 | 2025-06-20 | ||
| 4 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2025-10-01 | France | 2025-10-01 | |
| 5 | NON SUBSTANTIAL MODIFICATION | NSM-2 | 2025-10-01 | France | 2025-10-01 | |
| 6 | NON SUBSTANTIAL MODIFICATION | NSM-3 | 2025-12-05 | France | 2025-12-05 | |
| 7 | SUBSTANTIAL MODIFICATION | SM-3 | 2026-01-27 | France | Acceptable 2026-04-10
|
2026-04-13 |
| 8 | NON SUBSTANTIAL MODIFICATION | NSM-4 | 2026-04-22 | France | Acceptable 2026-04-10
|
2026-04-22 |